Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
Weiss A, Li T, Desai N, Tung N, Poorvu P, Partridge A, Nakhlis F, Dominici L, Sinclair N, Spring L, Faggen M, Constantine M, Krop I, DeMeo M, Wrabel E, Alberti J, Chikarmane S, Tayob N, King T, Tolaney S, Winer E, Mittendorf E, Waks A. Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. Journal Of The American College Of Surgeons 2023, 237: 247-256. PMID: 37194964, DOI: 10.1097/xcs.0000000000000761.Peer-Reviewed Original ResearchConceptsBreast conservation therapyTrastuzumab/pertuzumabBreast cancerTumor downsizingSystemic therapyBCT ratesSingle-arm prospective clinical trialBreast pathologic complete responseSingle-arm prospective trialBreast cancer warrants further investigationBCT-eligible patientsBreast size ratioCancer warrants further investigationEarly-stage HER2Neoadjuvant systemic therapyPathologic complete responseProspective clinical trialsWarrants further investigationBCT eligibilityMulticentric tumorsNeoadjuvant regimensProspective trialComplete responseLocal therapyConservation therapy